肿瘤细胞外囊泡来源的PD-L1通过脂质代谢重编程促进T细胞衰老
肿瘤来源细胞外囊泡(tEVs)可诱导T细胞衰老和抑制,其关键组分PD-L1在人及小鼠T细胞中引起DNA损伤和脂质代谢亢进,上调脂质代谢酶并增加胆固醇和脂滴形成,导致细胞衰老。抑制EV合成或阻断CREB信号、胆固醇合成及脂滴形成,可在体外和体内逆转tEV介导的T细胞衰老,并增强过继T细胞疗法和抗PD-L1免疫检查点疗法的抗肿瘤疗效。
要点
- 肿瘤来源细胞外囊泡(tEVs)诱导人及小鼠T细胞衰老和抑制。
- tEVs中的PD-L1激活CREB和STAT信号,促进脂质代谢和T细胞衰老。
- 抑制EV合成或阻断CREB信号、胆固醇合成及脂滴形成可逆转T细胞衰老并增强抗肿瘤免疫疗效。
核心结论
- 肿瘤来源细胞外囊泡(tEVs)通过PD-L1激活CREB和STAT信号促进脂质代谢重编程,诱导T细胞衰老和抑制,抑制该通路可增强过继T细胞疗法和抗PD-L1免疫检查点疗法的抗肿瘤疗效。
研究设计与样本
- 研究采用人及小鼠T细胞、细胞过继转移模型和黑色素瘤小鼠模型,进行体外和体内实验。
主要发现
- tEVs中的PD-L1在人及小鼠T细胞中诱导DNA损伤和脂质代谢亢进,上调脂质代谢酶并增加胆固醇和脂滴形成,导致细胞衰老。
- tEVs来源的PD-L1激活CREB和STAT信号,促进人及小鼠T细胞脂质代谢和衰老。
- 抑制肿瘤EV合成或阻断效应T细胞中CREB信号、胆固醇合成及脂滴形成,在体外及细胞过继转移和黑色素瘤小鼠模型中逆转tEV介导的T细胞衰老。
- 上述相同处理在人及小鼠黑色素瘤模型中增强过继转移T细胞疗法和抗PD-L1免疫检查点疗法的抗肿瘤疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The limited success of cancer immunotherapy has posed challenges in treating patients with cancer. However, promising strides could be made with a deeper understanding of the factors that cause T cell dysfunction within the tumor microenvironment and by developing effective strategies to counteract tumor-induced immune suppression. Here, we report that tumor-derived extracellular vesicles (tEVs) can induce senescence and suppression in T cells. Programmed death ligand 1 (PD-L1), a key component within tEVs, induced DNA damage and hyperactive lipid metabolism in both human and mouse T cells. This caused an elevated expression of lipid metabolic enzymes and an increase in cholesterol and lipid droplet formation, leading to cellular senescence. At a molecular level, PD-L1 derived from tEVs activated the cAMP-response element binding protein (CREB) and signal transducer and activator of transcription (STAT) signaling, which promoted lipid metabolism and facilitated senescence in human and mouse T cells. Inhibiting EV synthesis in tumors or blocking CREB signaling, cholesterol synthesis, and lipid droplet formation in effector T cells averted the tEV-mediated T cell senescence in vitro and in vivo in cell adoptive transfer and melanoma mouse models. The same treatments also bolstered the antitumor efficacy of adoptive transfer T cell therapy and anti-PD-L1 checkpoint immunotherapy in both human and mouse melanoma models. These studies identified mechanistic links between tumor-mediated immune suppression and potential immunotherapy resistance, and they provide new strategies for cancer immunotherapy.
引用
- Ma F, Liu X, Zhang Y, et al. Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci Transl Med. 2025. PMID: 39937879. doi:10.1126/scitranslmed.adm7269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。